poisar

Stocks · News reference

What's Going on With Novo Nordisk Stock on Friday?

Vandana Singh

Novo Nordisk eyes M&A to counter patent cliff risks, and partners with Nanexa for long-acting injectables.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NVO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Adria Cimino

    Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

    Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.

    VKTXLLYNVO
  3. Zacks.Com

    Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?

    Novo Nordisk received positive regulatory recommendations in Europe for Frehemgo (hemophilia A treatment) and Sogroya (growth hormone therapy for multiple indications), potentially diversifying revenue beyond its pressured GLP-1 portfolio. However, the company faces intensifying competition from Eli Lilly's blockbuster GLP-1 drugs and smaller biotechs, with Novo's stock underperforming the industry year-to-date.

    NVOLLYVKTXGPCR